Semaglutide Weight Loss by Month: What the Trial Data Actually Shows

If you have just started semaglutide, or are thinking about it, the question underneath all the others is usually about timing: how much will I lose, and how fast? The honest answer is that weight loss on these drugs is a slow build, not a switch that flips. The best data we have comes from the STEP 1 trial, and it tells a clear story — one that looks very different at month one than it does at month twelve. Before you read anyone’s month-by-month promise, it helps to see what “average” actually meant in the study. You can also map a rough personal estimate with our GLP-1 Weight-Loss Projector, keeping in mind that any projection is a ballpark, not a guarantee.

The headline number, honestly framed

In STEP 1 — the pivotal 68-week trial of once-weekly semaglutide 2.4 mg (Wegovy) in adults with overweight or obesity — participants lost a mean of 14.9% of their body weight, compared with 2.4% in the placebo group. That roughly 15% figure is the number you see quoted everywhere, and it is real.

But the word doing the heavy lifting is mean. It is an average across nearly two thousand people, and the spread around it was wide. In the same trial, 86.4% of people on semaglutide lost at least 5% of their body weight, 69.1% lost at least 10%, and 50.5% lost at least 15%. Read those the other way: a meaningful minority lost less than 5%, and about half did not reach 15%. Some people lost more than 20%. “About 15%” is the center of a broad distribution, not a target everyone lands on.

Why the first months are slow

The most common early disappointment is that the scale barely moves in month one. This is expected, and it is built into how the drug is dosed.

Semaglutide is not started at its full strength. The label escalates the once-weekly dose in fixed four-week steps: 0.25 mg, then 0.5 mg, then 1.0 mg, then 1.7 mg, reaching the 2.4 mg maintenance dose at around week 16. The two lowest doses exist for tolerability — to let your gut adapt — not to drive appetite suppression. In other words, for the first month or two you are taking a deliberately sub-therapeutic dose. Real appetite effect, and the steeper part of the weight-loss curve, tends to arrive as the dose climbs and once you settle onto maintenance.

So a slow start is not a sign the drug “isn’t working for you.” It usually means you simply haven’t reached an effective dose yet. This is the same logic behind why slow titration wins on tolerability — the ramp trades early speed for a gentler side-effect curve.

A month-by-month trajectory (illustrative)

Here is the important caveat: STEP 1 reported its primary weight result at week 68, and the trajectory over time was progressive — loss began during titration, continued through the maintenance phase, and started to level off later in the study. The trial did not publish a tidy “X% per month” schedule, so the table below is an illustrative path to the trial’s ~15% average, not trial-reported monthly figures. It is anchored to two things we can verify: the dosing timeline, and the 68-week endpoint. Your own numbers will differ.

Phase	Approximate dose	Illustrative cumulative loss
Month 1 (weeks 1–4)	0.25 mg (starter)	~1–2%
Months 2–4 (weeks 5–16)	0.5 → 1.0 → 1.7 mg	~3–6%
Months 4–6 (weeks 17–26)	2.4 mg maintenance	~7–10%
Months 7–12 (weeks 27–52)	2.4 mg	~11–14%
Months 13–16 (weeks 53–68)	2.4 mg	~15% (trial average endpoint)

The shape matters more than any single cell. Loss is slowest at the start, fastest through the middle stretch once you are on or near maintenance, and then flattens as the year goes on. That late flattening is normal and expected — appetite and metabolism adapt, and the body defends a new set point. We cover why that happens, and what to do about it, in the GLP-1 weight-loss plateau explained.

What “normal” looks like — and when to reassess

Because the trajectory is a curve, judging progress too early is a trap. A quiet first month is ordinary. The more useful checkpoints come once you have had a few weeks at a meaningful dose.

A rough, honest frame:

First month: minimal loss is normal. You are on starter doses.
Months 2–4: loss usually becomes visible as the dose escalates. This is where most people first see the trend line bend.
Around months 4–6, on maintenance: this is a fairer point to assess response. Research on these drugs has consistently found that people who lose very little early on tend, on average, to lose less overall — early response carries some signal.

That last point is worth handling carefully. If your loss is very low several months in and on a full dose, it is a reason to talk with your prescriber — about dose, adherence, injection technique, diet, or whether a different medication fits better — not a reason to quit on your own or to double up doses. Individual response genuinely varies, and “slow” is not the same as “none.”

The honest version: an average, not a promise

It is easy to treat “15%” as a figure you are owed by week 68. It isn’t. STEP 1 measured what happened, on average, to a large group taking the maximum dose alongside lifestyle support, under trial conditions with strong adherence. Your result depends on a stack of variables the average washes out:

Dose reached. People who can’t tolerate 2.4 mg and settle lower often lose less than the trial average.
Adherence. Missed weeks, long pauses, and dose interruptions all pull results below the trial numbers.
Diet and activity. The medication reduces appetite; it does not override everything else. Trial participants also received lifestyle counseling.
Starting point and biology. Baseline weight, sex, and individual physiology all shifted results in the trial’s own subgroup analyses.

None of this is a reason for pessimism — a 5% to 15% loss is clinically meaningful and life-changing for many people. It is simply a reason to hold the headline number loosely. If you are weighing semaglutide against the other major option, our comparison of semaglutide vs tirzepatide puts their trial results side by side.

The takeaway

Semaglutide weight loss unfolds as a curve, not a countdown. The first month is usually slow by design; loss builds as the dose climbs to 2.4 mg, runs fastest through the middle of the year, and flattens later — landing, on average, near 15% at 68 weeks in STEP 1, with wide variation on either side. Treat the trial number as a well-lit reference point, not a personal quota. To sketch a rough estimate for your own starting weight and timeline, try the GLP-1 Weight-Loss Projector — and bring any real decisions about dose or progress to the prescriber who knows your situation.

This article is educational and not medical advice. Semaglutide is a prescription medication; dosing, expectations, and any changes should be decided with a qualified clinician.